Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 10 | 2024 | 500 | 4.420 |
Why?
|
| Antihypertensive Agents | 8 | 2024 | 161 | 3.210 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 598 | 2.110 |
Why?
|
| Atrial Fibrillation | 5 | 2023 | 170 | 1.970 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2019 | 23 | 1.730 |
Why?
|
| Diabetes Complications | 3 | 2021 | 114 | 1.730 |
Why?
|
| Medication Adherence | 6 | 2020 | 244 | 1.690 |
Why?
|
| Atherosclerosis | 3 | 2023 | 51 | 1.580 |
Why?
|
| Stroke | 6 | 2023 | 311 | 1.500 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 179 | 1.470 |
Why?
|
| Diabetes Mellitus | 4 | 2018 | 487 | 1.340 |
Why?
|
| Retrospective Studies | 17 | 2024 | 2447 | 1.310 |
Why?
|
| Humans | 35 | 2024 | 17611 | 1.300 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 86 | 1.300 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2023 | 531 | 1.260 |
Why?
|
| Aged | 21 | 2024 | 6095 | 1.250 |
Why?
|
| Warfarin | 3 | 2021 | 74 | 1.210 |
Why?
|
| Blood Pressure | 4 | 2024 | 298 | 1.170 |
Why?
|
| Middle Aged | 22 | 2024 | 7911 | 1.080 |
Why?
|
| Adult | 18 | 2023 | 7598 | 1.020 |
Why?
|
| Hypoglycemic Agents | 4 | 2016 | 268 | 1.020 |
Why?
|
| Aspirin | 2 | 2015 | 63 | 0.980 |
Why?
|
| Male | 23 | 2024 | 10008 | 0.960 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 748 | 0.920 |
Why?
|
| Anticoagulants | 3 | 2023 | 127 | 0.910 |
Why?
|
| Female | 22 | 2024 | 12608 | 0.900 |
Why?
|
| Embolism | 1 | 2023 | 6 | 0.880 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2021 | 53 | 0.880 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 7 | 0.870 |
Why?
|
| Hyperkalemia | 1 | 2023 | 16 | 0.860 |
Why?
|
| Comorbidity | 8 | 2020 | 594 | 0.810 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 26 | 0.780 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 1900 | 0.770 |
Why?
|
| Prevalence | 7 | 2022 | 884 | 0.760 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 14 | 0.740 |
Why?
|
| Health Expenditures | 2 | 2019 | 75 | 0.730 |
Why?
|
| Treatment Outcome | 6 | 2024 | 1259 | 0.720 |
Why?
|
| Health Care Costs | 2 | 2020 | 228 | 0.720 |
Why?
|
| Diabetic Retinopathy | 2 | 2018 | 18 | 0.720 |
Why?
|
| Hemorrhage | 2 | 2023 | 62 | 0.720 |
Why?
|
| Young Adult | 8 | 2023 | 2427 | 0.700 |
Why?
|
| Cholesterol, LDL | 2 | 2016 | 119 | 0.650 |
Why?
|
| Antiviral Agents | 1 | 2019 | 94 | 0.640 |
Why?
|
| Hepatitis C | 1 | 2019 | 65 | 0.640 |
Why?
|
| Risk Factors | 9 | 2023 | 3325 | 0.640 |
Why?
|
| Cost of Illness | 1 | 2018 | 92 | 0.600 |
Why?
|
| Societies, Medical | 1 | 2018 | 74 | 0.590 |
Why?
|
| Guideline Adherence | 1 | 2018 | 155 | 0.550 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 53 | 0.540 |
Why?
|
| Incidence | 4 | 2023 | 1255 | 0.520 |
Why?
|
| Adolescent | 7 | 2021 | 3651 | 0.520 |
Why?
|
| Blood Coagulation | 1 | 2015 | 2 | 0.510 |
Why?
|
| Quality of Life | 1 | 2019 | 507 | 0.510 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2015 | 24 | 0.500 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 44 | 0.500 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 114 | 0.480 |
Why?
|
| Natural Language Processing | 1 | 2015 | 57 | 0.480 |
Why?
|
| Mass Screening | 2 | 2018 | 661 | 0.470 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 171 | 0.470 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 197 | 0.470 |
Why?
|
| Managed Care Programs | 1 | 2016 | 325 | 0.460 |
Why?
|
| California | 6 | 2020 | 2284 | 0.460 |
Why?
|
| Quality of Health Care | 1 | 2016 | 326 | 0.460 |
Why?
|
| United States | 5 | 2022 | 3956 | 0.450 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 382 | 0.430 |
Why?
|
| Risk Assessment | 5 | 2023 | 1097 | 0.420 |
Why?
|
| Administration, Oral | 3 | 2023 | 85 | 0.400 |
Why?
|
| Electronic Health Records | 1 | 2015 | 681 | 0.350 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1309 | 0.330 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 238 | 0.330 |
Why?
|
| International Normalized Ratio | 2 | 2017 | 22 | 0.270 |
Why?
|
| Osteoarthritis | 2 | 2016 | 15 | 0.270 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 568 | 0.250 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1115 | 0.240 |
Why?
|
| Proteinuria | 1 | 2024 | 26 | 0.240 |
Why?
|
| Logistic Models | 2 | 2019 | 926 | 0.230 |
Why?
|
| Rivaroxaban | 1 | 2023 | 8 | 0.220 |
Why?
|
| Pyridones | 1 | 2023 | 8 | 0.220 |
Why?
|
| Dabigatran | 1 | 2023 | 8 | 0.220 |
Why?
|
| Aldosterone | 1 | 2023 | 2 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 710 | 0.220 |
Why?
|
| Time Factors | 2 | 2018 | 1086 | 0.220 |
Why?
|
| Potassium | 1 | 2023 | 16 | 0.220 |
Why?
|
| Creatinine | 1 | 2023 | 65 | 0.220 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 17 | 0.220 |
Why?
|
| Diuretics | 1 | 2022 | 17 | 0.210 |
Why?
|
| Age Factors | 3 | 2020 | 917 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 250 | 0.200 |
Why?
|
| Spironolactone | 1 | 2021 | 6 | 0.200 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2021 | 10 | 0.200 |
Why?
|
| Angioedema | 1 | 2021 | 6 | 0.200 |
Why?
|
| Kidney Diseases | 1 | 2021 | 53 | 0.190 |
Why?
|
| Bioprosthesis | 1 | 2021 | 2 | 0.190 |
Why?
|
| Heart Valves | 1 | 2021 | 4 | 0.190 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 20 | 0.190 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 9 | 0.190 |
Why?
|
| Drug Combinations | 1 | 2020 | 41 | 0.180 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 23 | 0.180 |
Why?
|
| Coinfection | 1 | 2020 | 30 | 0.180 |
Why?
|
| Recurrence | 1 | 2020 | 186 | 0.180 |
Why?
|
| Physicians | 1 | 2021 | 137 | 0.180 |
Why?
|
| Social Class | 1 | 2020 | 120 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 381 | 0.160 |
Why?
|
| Drug Monitoring | 2 | 2017 | 20 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 415 | 0.160 |
Why?
|
| Sex Factors | 1 | 2020 | 643 | 0.160 |
Why?
|
| Brain Ischemia | 2 | 2008 | 37 | 0.160 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 529 | 0.150 |
Why?
|
| Canada | 1 | 2017 | 66 | 0.140 |
Why?
|
| Ethnic Groups | 1 | 2020 | 485 | 0.140 |
Why?
|
| Testosterone | 1 | 2017 | 22 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2020 | 263 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 304 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2017 | 35 | 0.140 |
Why?
|
| Hospitalization | 2 | 2020 | 797 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2019 | 428 | 0.130 |
Why?
|
| Heart Failure | 1 | 2021 | 396 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2020 | 2570 | 0.130 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 14 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 709 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1210 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1322 | 0.120 |
Why?
|
| Algorithms | 1 | 2015 | 233 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 13 | 0.110 |
Why?
|
| Causality | 1 | 2013 | 40 | 0.110 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 417 | 0.110 |
Why?
|
| Budgets | 1 | 2011 | 5 | 0.100 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2010 | 25 | 0.090 |
Why?
|
| Cost Sharing | 1 | 2010 | 30 | 0.090 |
Why?
|
| Leukoaraiosis | 1 | 2008 | 1 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 262 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 501 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2023 | 189 | 0.050 |
Why?
|
| Orthomyxoviridae | 1 | 2020 | 5 | 0.050 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 15 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 38 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 102 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 287 | 0.040 |
Why?
|
| Androgens | 1 | 2017 | 12 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2017 | 5 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 22 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 64 | 0.040 |
Why?
|
| Models, Economic | 1 | 2011 | 19 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 91 | 0.020 |
Why?
|
| Probability | 1 | 2011 | 79 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 75 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 81 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 61 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 85 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 2 | 0.020 |
Why?
|
| Korea | 1 | 2008 | 9 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 8 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 8 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 6 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2008 | 90 | 0.020 |
Why?
|
| Brain | 1 | 2008 | 45 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 297 | 0.020 |
Why?
|
Concepts
(157)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(13)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->